8-K: Mallinckrodt Completes Endo Acquisition, Converts Entity to Limited Partnership and Delists Shares

Mallinckrodt plc has completed its acquisition of Endo, Inc., which subsequently converted into Endo LP, a Delaware limited partnership, and delisted its common stock from the OTCQX Best Market.

Summary

• Mallinckrodt plc acquired Endo, Inc. through a merger on July 31, 2025, with Endo, Inc. surviving as a wholly-owned subsidiary of Mallinckrodt.
• Each share of Endo common stock was converted into 0.2575 Mallinckrodt Ordinary Shares and approximately $1.31 in cash, with fractional shares paid in cash.
• Following the merger, on August 1, 2025, Endo, Inc. converted into Endo LP, a Delaware limited partnership, with all Company Common Stock converting into 100% of the partnership interest of Endo LP.
• Endo's common stock was delisted from the OTCQX Best Market on August 1, 2025, and the company will file a Form 15 with the SEC to suspend its reporting obligations.
• Outstanding Endo equity awards (time-based RSUs, performance-based PSUs, and long-term cash awards) were converted into Mallinckrodt equity or cash awards, with provisions for accelerated vesting upon certain employment terminations within 24 months post-merger.

Sentiment

Score: 7

Explanation: The filing details the successful completion of a pre-announced merger and subsequent corporate restructuring. While it signifies the end of Endo's independent public trading, the terms of the acquisition and the treatment of equity awards appear to be executed as planned, with some additional benefits for directors. The conversion to a limited partnership under Mallinckrodt is a standard post-acquisition move for operational efficiency.

Positives

• Endo shareholders received a combination of Mallinckrodt shares and cash for their holdings, completing the acquisition as planned.
• Equity award holders (employees and directors) received converted awards or cash, with accelerated vesting provisions for certain terminations, providing a clear path for their compensation.
• Non-employee directors received an aggregate incremental payment of approximately $645,000 for their RSU Awards, based on a higher valuation implied by Mallinckrodt's independent valuation.
• Certain non-employee directors received transaction bonuses totaling $550,000 for their efforts in completing the transaction.

Negatives

• Endo, Inc. common stock has been delisted from the OTCQX Best Market, removing its independent public trading status.
• Endo, Inc. will cease its public reporting obligations, reducing transparency and direct public oversight for the former entity.
• The Limited Partnership Agreement grants sole management control to the General Partner (ELP 2025 GP Limited), with the Limited Partner (Mallinckrodt plc) having no direct control or management authority over Endo LP affairs, centralizing power.

Risks

• The General Partner (ELP 2025 GP Limited) will be personally obligated for any debt, obligation, or liability of Endo LP, except as otherwise expressly provided by the Delaware Revised Uniform Limited Partnership Act or the Limited Partnership Agreement.
• The Limited Partner (Mallinckrodt plc) will not be obligated personally for any debt, obligation, or liability of Endo LP, except as otherwise expressly provided by the Delaware Revised Uniform Limited Partnership Act or the Limited Partnership Agreement.

Future Outlook

Endo LP will operate as a wholly-owned subsidiary of Mallinckrodt plc. The company will file a Form 15 with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, indicating a cessation of independent public financial disclosures for Endo.

Industry Context

This transaction represents a consolidation within the pharmaceutical or specialty pharmaceutical sector, where larger entities acquire smaller ones to expand portfolios, achieve synergies, or restructure operations. The conversion to a limited partnership structure under a parent company is a common post-acquisition strategy for operational and tax efficiency.

Management Changes

Corporate Governance

Related Party Transactions

• The entire transaction constitutes a related party transaction, as Mallinckrodt plc acquired Endo, Inc., making Endo a wholly-owned subsidiary.
• The subsequent conversion of Endo, Inc. to Endo LP involves Mallinckrodt plc as the Limited Partner and ELP 2025 GP Limited (an Irish company with the same registered office as Mallinckrodt plc) as the General Partner, establishing a related party relationship within the new partnership structure.

Stakeholder Impact

• Shareholders: Former Endo shareholders received cash and Mallinckrodt shares, ceasing to be direct shareholders of Endo and becoming shareholders of Mallinckrodt.
• Employees: Equity awards were converted to Mallinckrodt awards with provisions for accelerated vesting upon certain employment terminations, potentially offering retention incentives or severance benefits.
• Directors/Officers: The entire board of directors was replaced, and key officers ceased their roles, with new management appointed by Mallinckrodt. Specific compensation and severance packages were detailed for departing executives and transaction bonuses for non-employee directors.

Next Steps

• Endo LP will operate as a wholly-owned subsidiary of Mallinckrodt plc.
• The company will file a Form 15 with the Securities and Exchange Commission to suspend its reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934.
• Mr. Tursi's employment will terminate 60 days after the Effective Time, as per his separation agreement.
• Mr. Hirsch will continue as a senior advisor for a transition period, followed by a six-month consulting engagement.

Key Dates

Keywords

Merger, Acquisition, Limited Partnership, Delisting, Corporate Conversion, Mallinckrodt, Endo, SEC Filing, Corporate Governance, Equity Awards, Change of Control, Pharmaceuticals